Clinical efficacy and safety of imepitoin in comparison with phenobarbital for the control of idiopathic epilepsy in dogs

Journal of Veterinary Pharmacology and Therapeutics

Volumn 38, Issue 2, 2015, Pages 160-168

  Tipold, A ^a,b   Keefe, T J ^c   Loscher W ^a,b   Rundfeldt, C ^d   de Vries, F ^e  

^a UNIVERSITY OF VETERINARY MEDICINE HANNOVER   (Germany)

^b CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^c Veterinary Dentistry and Oral Surgery   (United States)

^d Drug Consulting Network   (Germany)

^e BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; GAMMA GLUTAMYLTRANSFERASE; IMEPITOIN; LIVER ENZYME; PHENOBARBITAL; ANTICONVULSIVE AGENT; IMIDAZOLE DERIVATIVE;

ABNORMAL FECES COMPOSITION; ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATAXIA; BEAGLE; CANINE MODEL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRY EYE; EYE DISCHARGE; EYELID DISEASE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GENERALIZED EPILEPSY; HISTOPATHOLOGY; HYPERACTIVITY; INCREASED APPETITE; LACRIMATION; MALE; NEUROLOGIC DISEASE; NICTITATING MEMBRANE; NONHUMAN; NYSTAGMUS; POLYDIPSIA; PRIORITY JOURNAL; REFLEX DISORDER; SALIVATION; SEDATION; SOMNOLENCE; TREATMENT DURATION; TREMOR; VOMITING; ANIMAL; CLINICAL TRIAL; DOG; DOG DISEASES; DOSE RESPONSE; EPILEPSY; MULTICENTER STUDY; VETERINARY;

CANIS FAMILIARIS;

ANIMALS; ANTICONVULSANTS; DOG DISEASES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; IMIDAZOLES; PHENOBARBITAL;

EID: 84924518312     PISSN: 01407783     EISSN: 13652885     Source Type: Journal    
DOI: 10.1111/jvp.12151     Document Type: Article

References (41)

1. Berendt, M., Gredal, H., Ersboll, A.K. & Alving, J. (2007) Premature death, risk factors, and life patterns in dogs with epilepsy. Journal of Veterinary Internal Medicine, 21, 754-759.
2. Bostom, A.G., Kronenberg, F. & Ritz, E. (2002) Predictive performance of renal function equations for patients with chronic kidney disease and normal serum creatinine levels. Journal of the American Society of Nephrology, 13, 2140-2144.
3. Dayrell-Hart, B., Steinberg, S.A., VanWinkle, T.J. & Farnbach, G.C. (1991) Hepatotoxicity of phenobarbital in dogs: 18 cases (1985-1989). Journal of the American Veterinary Medical Association, 199, 1060-1066.
4. European Agency for the Evaluation of Medicinal Products (EMEA) (2004). Guideline on procedures for competent authorities for pharmacovigilance information for veterinary medicinal products. Committee for Veterinary Medicinal Products (CVMP). EMEA/CVMP/345/98-Rev. 1-FINAL. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/10/WC500004997.pdf
5. European Medicines Agency (2011). Combined VeDDRA list of clinical terms for reporting suspected adverse reactions in animals and humans to veterinary medicinal products. EMA/CVMP/10418/2009-Rev.3. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094802.pdf
6. ® (imepitoin) (EMEA/V/C/002543/0000), http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/veterinary/002543/WC500140842.pdf (date last accessed: 5 April 2013).
7. Frey, H.H. & Löscher, W. (1985) Pharmacokinetics of anti-epileptic drugs in the dog: a review. Journal of Veterinary Pharmacology and Therapeutics, 8, 219-233.
8. Frey, H.H. & Schwartz-Porsche, D. (1985) Pharmacologic principles in the treatment of epilepsy in the dog and cat. Tierarztliche Praxis, 13, 541-549.
9. Fukunaga, K., Saito, M., Matsuo, E., Muto, M., Mishima, K., Fujiwara, M. & Orito, K. (2009) Long-lasting enhancement of CYP activity after discontinuation of repeated administration of phenobarbital in dogs. Research in Veterinary Science, 87, 455-457.
10. Gaskill, C.L., Miller, L.M., Mattoon, J.S., Hoffmann, W.E., Burton, S.A., Gelens, H.C., Ihle, S.L., Miller, J.B., Shaw, D.H. & Cribb, A.E. (2005) Liver histopathology and liver and serum alanine aminotransferase and alkaline phosphatase activities in epileptic dogs receiving phenobarbital. Veterinary Pathology, 42, 147-160.
11. Graham, R.A., Downey, A., Mudra, D., Krueger, L., Carroll, K., Chengelis, C., Madan, A. & Parkinson, A. (2002) In vivo and in vitro induction of cytochrome P450 enzymes in beagle dogs. Drug Metabolism and Disposition, 30, 1206-1213.
12. von Klopmann, T., Rambeck, B. & Tipold, A. (2007) Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. Journal of Small Animal Practice, 48, 134-138.
13. Löscher, W. (1993) Basic aspects of epilepsy. Current Opinion in Neurology and Neurosurgery, 6, 223-232.
14. Löscher, W. (1994) Neue Antiepileptika - ein Fortschritt für die Behandlung epileptischer Tiere. Kleintierpraxis, 39, 325-342.
15. Löscher, W. (2003) Pharmakologische Grundlagen zur Behandlung der Epilepsie bei Hund und Katze. Praktischer Tierarzt, 84, 574-587.
16. Löscher, W., Schwartz-Porsche, D., Frey, H.H. & Schmidt, D. (1985) Evaluation of epileptic dogs as an animal model of human epilepsy. Arzneimittel-Forschung, 35, 82-87.
17. Löscher, W., Potschaka, H., Rieck, S., Tipold, A. & Rundfeldt, C. (2004) Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. Epilepsia, 45, 1228-1239.
18. Löscher, W., Hoffmann, K., Twele, F., Potschka, H. & Töllner, K. (2013) The novel antiepileptic drug imepitoin compares favourably to other GABA-mimetic drugs in a seizure threshold model in mice and dogs. Pharmacological Research, 77, 39-46.
19. Mariani, C.L. (2013) Terminology and classification of seizures and epilepsy in veterinary patients. Topics in Companion Animal Medicine, 28, 34-41.
20. Oberbauer, A.M., Grossmann, D.I., Irion, D.N., Schaffer, A.L., Eggleston, M.L. & Famula, T.R. (2003) The genetics of epilepsy in the Belgian Tervuren and sheep dog. Journal of Heredity, 94, 57-63.
21. Patterson, E.N. (2013) Epileptogenesis and companion animals. Topics in Companion Animal Medicine, 28, 42-45.
22. Podell, M. (1996) Seizures in dogs. Veterinary Clinics of North America: Small Animal Practice, 26, 779-809.
23. Podell, M. (1998) Antiepileptic drug therapy. Clinical Techniques in Small Animal Practice, 13, 185-192.
24. Potschka, H., Fischer, A., von Rüden, E.L., Hülsmeyer, V. & Baumgärtner, W. (2013) Canine epilepsy as a translational model? Epilepsia, 54, 571-579.
25. Rieck, S., Rundfeldt, C. & Tipold, A. (2006) Anticonvulsant activity and tolerance of ELB138 in dogs with epilepsy: a clinical pilot trial. The Veterinary Journal, 172, 86-95.
26. Rostock, A., Tober, C., Dost, R. & Bartsch, R. (1998a) Anxiolytic effects without sedation and amnesia of AWD 131-138 in animals. A comparison with diazepam and buspirone. Naunyn-Schmiedeberg's Archives of Pharmacology, 357 (Suppl. 4), R97.
27. Rostock, A., Tober, C., Dost, R. & Bartsch, R. (1998b) AWD 131-138 is a potential novel anxiolytic without sedation and amnesia: a comparison with diazepam and buspirone. Naunyn-Schmiedeberg's Archives of Pharmacology, 358(Suppl. 1), P35.
28. Rostock, A., Tober, C., Dost, R. & Bartsch, R. (1998c) AWD 131-138: anxiolytic and anticonvulsant activities without side effects in animals. Behavioural Pharmacology, 9(Suppl. 1), 79.
29. Rostock, A., Tober, C., Dost, R., Rundfeldt, C., Bartsch, R., Egerland, U., Stark, B., Schupke, H., Kronbach, T., Lankau, H.J., Unverferth, K. & Engel, J. (1998d) AWD 131-138. Drugs of the Future, 23, 253-255.
30. Rundfeldt, C. & Löscher, W. (2014) The pharmacology of imepitoin: the first partial benzodiazepine receptor agonist developed for the treatment of epilepsy. CNS Drugs, 28, 29-43.
31. Rundfeldt, C., Gasparic, A. & Wlaz, P. (2014) Imepitoin as novel treatment option for canine idiopathic epilepsy: pharmacokinetics, distribution, and metabolism in dogs. Journal of Veterinary Pharmacology and Therapeutics, 37, 421-434.
32. Schmidt, D., Kupferberg, H.J., Yonekawa, W. & Penry, J.K. (1978) Development of tolerance of phenobarbital after administration over several days. Arzneimittelforschung (Drug Research), 28, 1515-1516.
33. Schwartz-Porsche, D., Löscher, W. & Frey, H.H. (1985) Therapeutic efficacy of phenobarbital and primidone in canine epilepsy: a comparison. Journal of Veterinary Pharmacological Therapy, 8, 113-119.
34. Shihab, N., Bowen, J. & Volk, H.A. (2011) Behavioral changes in dogs associated with the development of idiopathic epilepsy. Epilepsy & Behavior, 21, 160-167.
35. Sigel, E., Baur, R., Netzer, R. & Rundfeldt, C. (1998) The antiepileptic drug AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Neuroscience Letters, 245, 85-88.
36. Smith, P.M., Talbot, C.E. & Jeffery, N.D. (2008) Findings on low-field cranial MR images in epileptic dogs that lack interictal neurological deficits. The Veterinary Journal, 176, 320-325.
37. Steinmetz, S., Tipold, A. & Löscher, W. (2013) Epilepsy after head injury in dogs: a natural model of posttraumatic epilepsy. Epilepsia, 54, 580-588.
38. Thomas, W.B. & Dewey, C.W. (2008). Seizures and narcolepsy. In A Practical Guide to Canine and Feline Neurology. Ed Dewey, C.W., pp. 237-259. Wiley Blackwell, Hoboken, NJ.
39. Trepanier, L.A., Van Schoick, A., Schwark, W.S. & Carrillo, J. (1998) Therapeutic serum drug concentrations in epileptic dogs treated with potassium bromide alone or in combination with other anticonvulsants: 122 cases (1992-1996). Journal of the American Veterinary Medical Association, 213, 1449-1453.
40. Wiglusz, M.S., Cubala, W.J., Galuszko-Wegielnik, M., Jakuszkowiak-Wojten, K. & Landowski, J. (2012) Mood disorders in epilepsy - diagnostic and methodological considerations. Psychiatria Danubina, 24(Suppl. 1), S44-S50.
41. Wismer, T.A. (2002) Accidental ingestion of alprazolam in 415 dogs. Veterinary and Human Toxicology, 44, 22-23.